2,3-Di-thiophen-2-yl-quinoxaline-6,7-diol | 861883-43-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,3-Di-thiophen-2-yl-quinoxaline-6,7-diol
• 英文别名: 2,3-dithiophen-2-ylquinoxaline-6,7-diol
• CAS: 861883-43-4
• 化学式: C₁₆H₁₀N₂O₂S₂
• 分子量: 326.4
• InChiKey: DKWQFKCOHCSXOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,3-Di-thiophen-2-yl-quinoxaline-6,7-diol 在 sodium hydroxide 、 TEA 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 6,7-Di-thiophen-2-yl-2,3-dihydro-1,4-dioxa-5,8-diaza-anthracene-2-carboxylic acid
  参考文献：
  名称：

  Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives

  摘要：

  SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined Log P and Log S values. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.064
• 作为产物：
  描述：

  1,2-二氨基-4,5-二甲氧基苯 在 氢溴酸 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 2,3-Di-thiophen-2-yl-quinoxaline-6,7-diol
  参考文献：
  名称：

  Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives

  摘要：

  SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined Log P and Log S values. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.064

文献信息

• Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives
  作者：Zsolt Székelyhidi、János Pató、Frigyes Wáczek、Péter Bánhegyi、Bálint Hegymegi-Barakonyi、Dániel Ero˝s、György Mészáros、Ferenc Hollósy、Doris Hafenbradl、Sabine Obert、Bert Klebl、György Kéri、László O˝rfi

  DOI：10.1016/j.bmcl.2005.04.064

  日期：2005.7

  SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined Log P and Log S values. (c) 2005 Elsevier Ltd. All rights reserved.